Ribon Therapeutics
Laura Brass, Ph.D., M.B.A. has served as a member of the board of directors since April 2021. Dr. Brass is a Managing Director at NVF in Cambridge, MA, USA. Prior to joining NVF, Laura was a Managing Director at MPM Capital, and prior to that, she was a member of the founding management team and SVP of Business Development for TriNetX, a healthcare IT company focusing on big data analytics of live patient data for clinical research. Laura has also held roles in business development and IP strategy at Elixir Pharmaceuticals, and was CEO of Aferon, Inc., an early-stage antiviral start-up company. Laura holds a B.A. in Philosophy and a B.S. in Biochemistry from the University of Missouri-Columbia, and a Ph.D. in Molecular Genetics and Cell Biology and an M.B.A. from the University of Chicago.
This person is not in the org chart
Ribon Therapeutics
Ribon is a clinical-stage biotechnology company dedicated to the discovery and development of first-in-class small molecule inhibitors to block the fundamental ability of cancer cells to survive under stress.